Pyrrole

Summary

Pyrrole (CHEMBL16225) is an approved small molecule; indicated across 1 condition including aspergillosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 67.09 Da · C4H5N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL16225
Name	Pyrrole
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	8027
ChEBI	CHEBI:19203
Molecular formula	C4H5N
Molecular weight	67.09
InChIKey	KAESVJOAVNADME-UHFFFAOYSA-N

SMILES: C1=CNC=C1

IUPAC name: 1H-pyrrole

ChEBI definition: A tautomer of pyrrole that has the double bonds at positions 2 and 4.

Also known as: 1h-pyrrole, Azole, Divinylenimine, FEMA NO. 3386, Imidole, NSC-62777, Pyrrole, 1H-Pyrrole, pyrrole, PYRROLE

Patent coverage: 164,206 distinct patent families (413,479 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 413,444 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
aspergillosis	3	MONDO:0005657	EFO:0007157

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04876716	PHASE3	TERMINATED	Azole-echinocandin Combination Therapy for Invasive Aspergillosis
NCT03659162	Not specified	UNKNOWN	Efflux Pump Mediated Azole Resistance in Candida Albicans
NCT05795491	Not specified	COMPLETED	Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).